Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Loteprednol Etabonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 14/20 | 1.00 |
| ▸ | PGR | P06401 | 7/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.75 |
| ▸ | LMNA | P02545 | 3/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
| ▸ | USP2 | O75604 | 1/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | TNF | P01375 | 1/20 | 0.57 |
| ▸ | IL6 | P05231 | 1/20 | 0.57 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.57 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.57 |
| ▸ | AR | P10275 | 1/20 | 0.57 |
| ▸ | GLUL | P15104 | 1/20 | 0.57 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.57 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Loteprednol Etabonate SCHEMBL23907 | 1.00 | NR3C1 (1.00) | NR3C1PGRABCB11NR1I2ABCC3 | |
| Loteprednol Etabonate SCHEMBL3822250 | 1.00 | NR3C1 (1.00) | NR3C1PGRABCB11NR1I2ABCC3 | |
| Loteprednol Etabonate SCHEMBL12738239 | 1.00 | NR3C1 (1.00) | NR3C1PGRABCB11NR1I2ABCC3 | |
| Loteprednol Etabonate SCHEMBL12045348 | 1.00 | NR3C1 (1.00) | NR3C1PGRABCB11NR1I2ABCC3 | |
| Loteprednol Etabonate SCHEMBL669340 | 1.00 | NR3C1 (1.00) | NR3C1PGRABCB11NR1I2ABCC3 | |
| Loteprednol Etabonate SCHEMBL15325052 | 1.00 | NR3C1 (1.00) | NR3C1PGRABCB11NR1I2ABCC3 | |
| Loteprednol Etabonate SCHEMBL23765700 | 1.00 | NR3C1 (1.00) | NR3C1PGRABCB11NR1I2ABCC3 | |
| Loteprednol Etabonate SCHEMBL3413440 | 1.00 | NR3C1 (1.00) | NR3C1PGRABCB11NR1I2ABCC3 | |
| Loteprednol Etabonate SCHEMBL13379816 | 1.00 | NR3C1 (1.00) | NR3C1PGRABCB11NR1I2ABCC3 | |
| Loteprednol Etabonate SCHEMBL22078123 | 1.00 | NR3C1 (1.00) | NR3C1PGRABCB11NR1I2ABCC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1744759-B1 | USE OF LOTEPREDNOL ETABONATE FOR THE TREATMENT OF DRY EYE | BAUSCH & LOMB (US) | 2009-09-02 | — | — | EP | claimed |
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | EPIGENESIS PHARMACEUTICALS, LLC | 2007-01-25 | — | — | US | claimed |
| US-20050222110-A1 | Use of loteprednol etabonate for the treatment of dry eye | BAUSCH & LOMB INCORPORATED | 2005-10-06 | — | — | US | claimed |
| US-20050182039-A1 | Use of Loteprednol etabonate for the treatment of dry eye | BAUSCH & LOMB INCORPORATED | 2005-08-18 | — | — | US | claimed |
| CN-117368390-B | Method for determining impurity substances of loteprednol etabonate bulk drug by high performance liquid chromatography | 济南辰欣医药科技有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117368390-A | Method for determining impurity substances of loteprednol etabonate bulk drug by high performance liquid chromatography | 济南辰欣医药科技有限公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20130079315-A1 | Ophthalmic Gel Compositions | SOLTA MEDICAL, INC. | 2013-03-28 | — | — | US | disclosed |
| US-20120028947-A1 | Ophthalmic Compositions | BAUSCH HEALTH COMPANIES INC. (CA) | 2012-02-02 | — | — | US | disclosed |
| US-20100234336-A1 | Ophthalmic Compositions | BAUSCH & LOMB INCORPORATED | 2010-09-16 | — | — | US | disclosed |
| EP-2127655-A1 | Use of loteprednol etabonate for the treatment of dry eye | BAUSCH & LOMB INCORPORATED (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-1744759-B1 | USE OF LOTEPREDNOL ETABONATE FOR THE TREATMENT OF DRY EYE | BAUSCH & LOMB (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2007058935-A2 | OPHTHALMIC COMPOSITION FOR DRY EYE THERAPY | BAUSCH & LOMB INCORPORATED (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070110812-A1 | Ophthalmic composition for dry eye therapy | BAUSCH & LOMB INCORPORATED | 2007-05-17 | — | — | US | disclosed |
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | EPIGENESIS PHARMACEUTICALS, LLC | 2007-01-25 | — | — | US | disclosed |
| EP-1744759-A2 | USE OF LOTEPREDNOL ETABONATE FOR THE TREATMENT OF DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005094836-A2 | USE OF LOTEPREDNOL ETABONATE FOR THE TREATMENT OF DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050222110-A1 | Use of loteprednol etabonate for the treatment of dry eye | BAUSCH & LOMB INCORPORATED | 2005-10-06 | — | — | US | disclosed |
| US-20050182039-A1 | Use of Loteprednol etabonate for the treatment of dry eye | BAUSCH & LOMB INCORPORATED | 2005-08-18 | — | — | US | disclosed |
| US-4996335-A | Soft steroids having anti-inflammatory activity | Bodor, Nicholas S. (US) | 1991-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | RECQL, GSS, DDX17 | NR3C1 104/4885PGR 965/4885ABCB11 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.